Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma

BMC Pediatrics

Volumn 9, Issue , 2009, Pages

  Noonan, Michael ^a   Leflein, Jeffrey ^b   Corren, Jonathan ^c   Staudinger, Heribert ^d  

^a Allergy Associates Research Center   (United States)

^b Allergy and Immunology Associates of Ann Arbor PC   (United States)

^c Allergy Research Foundation   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; HYDROCORTISONE; MOMETASONE FUROATE; ANTIALLERGIC AGENT; ANTIINFLAMMATORY AGENT; PREGNANE DERIVATIVE;

ARTICLE; ASTHMA; CHILD; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY POWDER; EVENING DOSAGE; FEMALE; HUMAN; HYDROCORTISONE URINE LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; MORNING DOSAGE; MULTICENTER STUDY; NOSE CONGESTION; PATIENT COMPLIANCE; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SINUSITIS; THRUSH; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; NEBULIZER; POWDER; PRESCHOOL CHILD;

ADMINISTRATION, INHALATION; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BECLOMETHASONE; CHILD; CHILD, PRESCHOOL; HUMANS; HYDROCORTISONE; NEBULIZERS AND VAPORIZERS; POWDERS; PREGNADIENEDIOLS;

EID: 68349150555     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-9-43     Document Type: Article

References (17)

1. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma 2007 http://www.nhlbi.nih.gov/guidelines/asthma/index.htm
2. Global strategy for asthma management and prevention, revised 2006 2006 http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=60
3. Karpel JP An easy-to-use dry-powder inhaler Adv Ther 2000, 17(6):282-286. 10.1007/BF02850011 11317831
4. Yang TT Li S Wyka B Kenyon D Drug delivery performance of the mometasone furoate dry powder inhaler J Aerosol Med 2001, 14(4):487-494. 10.1089/ 08942680152744695 11791689
5. Bernstein DI Berkowitz RB Chervinsky P Dvorin DJ Finn AF Gross GN Karetzky M Kemp JP Laforce C Lumry W Mendelson LM Nelson H Pearlman D Rachelefsky G Ratner P Repsher L Segal AT Selner JC Settipane GA Wanderer A Cuss FM Nolop KB Harrison JE Dose-ranging study of a new steroid for asthma: Mometasone furoate dry powder inhaler Respir Med 1999, 93(9):603-612. 10.1016/S0954-6111(99)90099-9 10542973
6. Bousquet J D'Urzo A Hebert J Barraza CH Boulet LP Suarez-Chacon R Harnest U Lundback B Martinez Morales G Nieminen MM Nolop KB Visser S Lutsky BN Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler Eur Respir J 2000, 16(5):808-816. 10.1183/09031936.00.16580800 11153576
7. Noonan M Karpel JP Bensch GW Ramsdell JW Webb DR Nolop KB Lutsky BN Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler Ann Allergy Asthma Immunol 2001, 86(1):36-43. 11206236
8. Asmanex® Twisthaler® (mometasone furoate inhalation powder) Full Prescribing Information, Schering Corporation, Kenilworth, NJ 2008.
9. Bacharier LB Raissy HH Wilson L McWilliams B Strunk RC Kelly HW Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma Pediatrics 2004, 113(6):1693-1699. 10.1542/peds.113.6.1693 15173493
10. Irani AM Cruz-Rivera M Fitzpatrick S Hoag J Smith JA Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma Ann Allergy Asthma Immunol 2002, 88(3):306-312. 11926625
11. Leflein JG Gawchik SM Galant SP Lyzell E Young M Cruz-Rivera M Walton-Bowen K Smith JA Fitzpatrick S Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma Allergy Asthma Proc 2001, 22(6):359-366. 11775393
12. Silverman M Sheffer AL Diaz PV Lindberg B Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial Pediatr Allergy Immunol 2006, 17(Suppl 17):14-20. 10.1111/j.1600-5562.2006.00380.x 16573704
13. MacKenzie CA Tsanakas J Tabachnik E Radford M Berdel D Gotz MH Parker C An open study to assess the long-term safety of fluticasone propionate in asthmatic children. International Study Group Br J Clin Pract 1994, 48(1):15-18. 8179974
14. Todd GR Acerini CL Ross-Russell R Zahra S Warner JT McCance D Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom Arch Dis Child 2002, 87(6):457-461. 1755820 12456538 10.1136/ adc.87.6.457
15. Skoner D Gentile D Angelini B Twice-daily treatment with mometasone furoate dry-powder inhaler 100 mg did not exert a systemic effect as measured by plasma cortisol levels: Findings from a pediatric asthma placebo-controlled clinical trial [Abstract] Chest 2007, 132:602S.
16. Skoner D Dunn M Lee T Effects of mometasone furoate dry powder inhaler on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma [Abstract] Am J Respir Crit Care Med 2003, 167:A272.
17. Lemanske R Lockey R Murphy K Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma [abstract] Eur Respir J 2004, 24:378s. 10.1183/ 09031936.04.00113003